NCT06645886 - A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

December 9, 2024

Primary Completion Date

August 31, 2027

Study Completion Date

February 29, 2028

Conditions

Hematologic MalignanciesAdult

Interventions

DRUG

KQB198

Oral KQB198

DRUG

Dasatinib

Oral dasatinib

Trial Locations (21)

13005

RECRUITING

AP-HM - Hopital de la Timone, Marseille

22031

RECRUITING

Virginia Cancer Specialists, Fairfax

27710

RECRUITING

Duke University Medical Center, Durham

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

28046

RECRUITING

Hospital Universitario La Paz, Madrid

29010

RECRUITING

Hospital Regional Universitario de Malaga, Málaga

33612

RECRUITING

Moffitt Cancer Center, Tampa

37044

RECRUITING

CHRU de Tours - Hopital Bretonneau, Tours

37203

RECRUITING

Sarah Cannon Research Institute (SCRI) - Transplant and Cellular Therapy Operations, Nashville

40138

RECRUITING

IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola, Bologna

45236

RECRUITING

Oncology Hematology Cincinnati, Cincinnati

48201

RECRUITING

Barbara Ann Karmanos Cancer Institute, Detroit

77030

RECRUITING

MD Anderson Cancer Center, Houston

78731

RECRUITING

Texas Oncology Austin Central, Austin

80218

RECRUITING

Colorado Blood Cancer Institute, Denver

94143

RECRUITING

University of California, San Francisco (UCSF), San Francisco

07747

RECRUITING

Universitaetsklinikum Jena, Jena

00168

RECRUITING

Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Rome

60-185

RECRUITING

Aidport Sp. z o.o., Poznan

80-214

RECRUITING

Copernicus PL Sp. z o.o., Wojewodzkie Centrum Onkologii, Gdansk

40-519

RECRUITING

Pratia Onkologia Katowice, Katowice